Vigabatrin 500mg Sachets

Vigabatrin 500 mg Sachets contain vigabatrin, an antiepileptic medicine used to treat specific seizure disorders. It works by increasing the availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that helps regulate electrical activity in the brain.

The sachet formulation contains 500 mg of vigabatrin as granules or powder for oral solution. The contents must be prepared according to the official product instructions before administration.

Vigabatrin is prescribed for selected patients with treatment-resistant epilepsy and, where authorized, certain cases of infantile spasms. Treatment requires specialist supervision because the medicine can cause potentially permanent vision loss.

Product Information

Product Name

Vigabatrin 500 mg Sachets

Active Ingredient

Vigabatrin

Strength

500 mg per sachet

Dosage Form

Granules or powder for oral solution

Drug Class

Antiepileptic medicine

Route of Administration

Oral, after preparation

Common Brand Reference

Sabril

Pack Size

Confirm the available packaging

Manufacturer

Verify the actual product label

Prescription Requirement

Subject to local regulations

Ordering and Availability

For Vigabatrin 500 mg sachet pricing, pack sizes and availability, contact the supplier to verify the exact product, manufacturer, current stock and packaging details.

Availability, product authorization, prescription requirements and import eligibility vary by country. Confirm local regulations and obtain the medicine through an authorized pharmacy or eligible supplier.

Vigabatrin 500 mg sachets may be prescribed for:

• Treatment-Resistant Partial Seizures: Used alongside other antiepileptic medicines when appropriate treatments have not adequately controlled seizures or have not been tolerated.
• Infantile Spasms: Used in selected infants where the specific product is authorized for this indication and a specialist determines that treatment is appropriate.

Approved indications vary by product and country. A neurologist or other qualified specialist should determine whether vigabatrin is suitable.

Take Vigabatrin 500 mg Sachets exactly as prescribed by the treating specialist. The dose and schedule depend on the patient's age, weight, diagnosis, kidney function and response to treatment.

Prepare the sachet contents using the liquid and method specified in the product leaflet. Measure the prescribed amount carefully using an appropriate oral dosing device when required. Follow the product-specific instructions for administration and use the prepared solution promptly as directed.

Do not change the dose, use a different preparation method or discontinue treatment suddenly without medical advice.

Storage Instructions

Store the unopened sachets according to the manufacturer's packaging and official patient leaflet. Keep the medicine out of the reach of children and do not use it after the expiry date.

Prepare the oral solution only as instructed. Follow the product-specific directions for how soon the prepared solution must be administered and whether any unused portion must be discarded.

Possible adverse effects include:

• Tiredness or pronounced sleepiness
• Dizziness or headache
• Weight gain
• Tremor or reduced coordination
• Nausea, vomiting or abdominal discomfort
• Mood or behavioural changes
• Blurred vision or other visual disturbances

Important: Vigabatrin can cause narrowing of the visual field and potentially permanent vision loss. Visual damage may occur without obvious early symptoms. Baseline and regular eye examinations are essential during treatment, with follow-up as advised by the specialist.

Seek prompt medical advice for any new visual symptoms, significant behavioural changes, unusual drowsiness or worsening seizures. Serious or sudden symptoms require urgent medical assessment.

Before treatment, inform the prescriber about existing eye problems, kidney disease, mental health conditions, pregnancy or breastfeeding, and all medicines currently being taken.

Important precautions include:

• Vision monitoring: Regular assessments are needed because visual-field loss can be irreversible.
• Kidney function: Vigabatrin is eliminated through the kidneys, and dose adjustment may be necessary in patients with impaired kidney function.
• Mental health: Monitor for depression, significant behavioural changes or thoughts of self-harm.
• Other medicines: Tell the prescriber about all antiepileptic medicines and other treatments to assess possible interactions.
• Treatment withdrawal: Do not stop vigabatrin abruptly; discontinuation should be managed by the treating specialist.

The continued need for treatment should be reviewed periodically, balancing seizure control against potential risks.